Publikationen

Das dritte Update TDM in Psychiatry Konsensuspaper der AGNP WURDE Mitte 2017 in einem Sonderheft der Pharmacopsychiatry publiziert (free PMC article, siehe unten).

Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G (2004):
The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in Psychiatry.
Pharmacopsychiatry 2004; 37:243-265.

Fleischhaker C, Heiser P, Hennighausen K et al (2006):
Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics.
J Child Adolesc Psychopharmacol 2006; 16:308-316.

Fleischhaker C, Heiser P, Hennighausen K et al (2007):
Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Transm 2007; 114:273-280.

Fleischhaker C, Heiser P, Hennighausen K et al (2008):
Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone.
J Neural Transm DOI: 10.1007/s00702-008-0105-9.

Gerlach M, Hünnerkopf R, Rothenhöfer S, Libal G, Burger R, Clement H-W, Fegert JM, Wewetzer Ch, Mehler-Wex C:
Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders.
Pharmacopsychiatry 2007; 40:72-76.

Gerlach M, Klampfl K, Mehler-Wex C, Warnke A (2009):
Besonderheiten der Therapie mit Neuro-Psychopharmaka im Kindes- und Jugendalter.
In: Gerlach M, Mehler-Wex C, Walitza S, Warnke A, Wewetzer C (Hrsg.). Neuropsychopharmaka im Kindes- und Jugendalter. Grundlagen und Therapie. 2. Auflage. Wien, New York: Springer, 2009; 73-89.

Gerlach M, Klampfl K, Warnke A, Mehler-Wex C (2010):
Besonderheiten der Therapie mit Neuro-Psychopharmaka im Kindes- und Jugendalter, Psychopharmakotherapie
Arzneimitteltherapie psychischer und neurologischer Erkrankungen, 17. Jahrgang, Nr. 3, 2010; 118-125.

Gerlach M, Rothenhöfer S, Mehler-Wex C, Baumann P, Hiemke Ch, Eckermann G, Gärtner I, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Ulrich S, Zernig G, Wewetzer Ch (2005):
herapeutisches Drug Monitoring in der Kinder- und Jugendpsychiatrie.
Psychopharmakotherapie 2005; 4:118-120.

Gerlach M, Rothenhöfer S, Mehler-Wex C, Fegert JM, Schulz E, Wewetzer Ch, Warnke A (2006):
Therapeutisches Drug-Monitoring in der Kinder- und Jugendpsychiatrie - Grundlagen und praktische Empfehlungen.
Z Kinder-Jugendpsychiatr 2006; 34: 5-13.

Kirchheiner J, Brockmoller J (2005):
Clinical consequences of cytochrome P450 2C9 polymorphisms.
Clin Pharmacol Ther 2005; 77(1): 1-16.

Kirchheiner J, Brøsen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmöller J (2001):
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.
Acta Psychiatr Scand 2001; 104(3): 173-192.

Klampfl K, Mehler-Wex C, Warnke A, Gerlach M (2010):
Therapeutisches Drug-Monitoring in der Kinder- und Jugendpsychiatrie. Psychopharmakotherapie. Psychopharmakotherapie, Arzneimitteltherapie psychischer und neurologischer Erkrankungen,
17. Jahrgang, Nr. 4, 2010; 188 - 192.

Klampfl K, Taurines R, Preuss A, Burger R, Rothenhöfer S, Wewetzer C, Pfuhlmann B, Fegert J, Gerlach M, Mehler-Wex C (2010):
Serum Concentrations, Therapeutic Response and Side Effects in Children and Adolescents with Impulsive- Aggressive Symptoms during Risperidone Therapy.
Pharmacopsychiatry 2010; 43(2): 58-65.

Egberts KM, Mehler-Wex C, Gerlach M (2011):
Therapeutic drug monitoring in child and adolescent psychiatry.
Pharmacopsychiatry. 2011; 44: 249-253.

Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011):
GNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011;
Pharmacopsychiatry. 2011; 44: 195-235.

Klampfl K, Fleischmann Y, Wewetzer Ch et al. (2011):
Therapeutic Drug Monitoring in Children and adolescents during setraline therapy.
Poster Abstract. IX International Congress of the Interdisciplinary AGNP-TDM-Task Force, Sept 2010, Bolzano. Pharmacopsychiatry. 2011; 44: 274.

Karwautz A, Bangratz S, Huemer J (2011):
Qualitätssicherung in der kinder- und jugendpsychiatrischen Psychopharmakotherapie Einsatz von Therapeutic Drug Monitoring (TDM).
Pädiatrie und Pädologie. 2011; 46:10-13.

Bangratz SW, Huemer J, Koubek D, Laczkovics C, Kroenke H, Karwautz A (2011):
Therapeutic drug monitoring of duloxetine in child and adolescent psychiatry;
Poster Abstract. 12th International Congress of TDM & Clinical Toxicology, Oktober 2011, Stuttgart. Ther Drug Monit 33(4): August 2011.

Hansen D, Taurines R, Wewetzer Ch, Pfuhlmann B, Plener P, Mehler-Wex C, Gerlach M, Egberts K (2012)
Therapeutic drug monitoring (TDM) in children and adolescents treated with aripiprazole
Poster Abstract - 10. Jahrestagung der Schweizerischen Gesellschaft für Arzneimittelsicherheit in der Psychiatrie - Wissenschaftliche Tagung zu Psychopharmaka: Risiken und Risikomanagement 26.-28.09.2012 in Brugg

Karwautz A, Moyses M , Huemer J, Mader S, Bangratz, SW, Koubeck D, Laczkovics Z, Krönke H, Skala K, Egberts K (2012).
Olanzapine in adolescents anorexia nervosa: a pilot study using therapeutic drug monitoring
Poster Abstract - Eating Disorders Research Society 18th Annual Meeting Porto, Portugal September 20 - 22, 2012

Koelch M, Pfalzer A-K, Kliegl K, Rothenhöfer S, Ludolph A G, Fegert J M, Burger R, Mehler-Wex C, Stingl J, Taurines R, Egberts K M, Gerlach M (2012).
Therapeutic drug monitoring of children and adolescents treated with fluoxetine
Pharmacopsychiatry;45(02):72-76.

Kulpok C, Taurines R, Wewetzer Ch, Pfuhlmann B, Plener P, Mehler-Wex C, Gerlach M, Egberts K (2012):
Relation between dosage, serum concentration and therapeutic response of quetiapine in children and adolescents with different psychiatric disorders in clinical practice.
Poster Abstract - 10. Jahrestagung der Schweizerischen Gesellschaft für Arzneimittelsicherheit in der Psychiatrie - Wissenschaftliche Tagung zu Psychopharmaka: Risiken und Risikomanagement 26.-28.09.2012 in Brugg

Taurines R, Burger R, Wewetzer Ch, Pfuhlmann B, Mehler-Wex C, Gerlach M, Egberts K. (2013):
The relation between dosage, serum concentrations and clinical outcome in children and adolescents treated with sertraline: a naturalistic study.
The Drug Monitoring 2013 Feb.;35(1):84-91

Egberts K, Preuss A, Wewetzer C, Unterecker S, Plener P, Gerlach M (2014):
Pharmacovigilance in children and adolescents with psychiatric disorders.
Pharmacopsychiatry 2014;47:219-229

Egberts K, Dang SY, Plener P, Romanos M, Gerlach M (2014):
Relation between dosage, serum concentration and therapeutic response of risperidone in children and adolescents with schizophrenic psychosis: data from a routine TDM-service.
Pharmacopsychiatry 2014;47:219-229

Dang SY, Jeutter V, Gerlach M, Romanos M, Taurines R, Egberts K (2014):
Aripiprazole induced extrapyramidal symptoms in two adolescents.
Pharmacopsychiatry 2014;47:219-229

Egberts K, Karwautz A, Plener P, Mehler-Wex C, Kölch M, Dang SY, Taurines R, Romanos M, Gerlach M (2014):
Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry,
Expert Opinion on Drug Safety, DOI: 10.1080/14740338.2016.1225721

Wohkittel C, Gerlach M, Taurines R, Wewetzer C, Unterecker S, Burger R, Schreck D, Mehler-Wex C, Romanos M, Egberts K. (2016):
Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice.
Journal of Neural Transmission 2016; 123(8), 1021-1031

Gerlach M, Warnke A (2016):
Editorial. Medikamentöse Behandlung in der Kinder- und Jugendpsychiatrie in Deutschland zwischen ethischen, sozial- und haftungs­rechtlichen Konflikten.
Z Kinder-Jugendpsychiatr Psychother 44: 249-255

Albantakis L, Egberts K, Burger R, Kulpok C, Mehler-Wex C, Taurines R, Unterecker S, Wewetzer C, Romanos M, Gerlach M (2017)
Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry.
Expert Opin Drug Saf. 2016 Nov;15(11):1477-1482

Gerlach M, Egberts K, Dang SY, Plener P, Taurines R, Mehler-Wex C, Romanos M:
Relationship Between Daily Dose, Serum Concentration, and Clinical Response to Quetiapine in Children and Adolescents with Psychotic and Mood Disorders.
Pharmacopsychiatry. 2017 Nov;50(6):248-255

Fekete S, Wewetzer C, Mehler-Wex C, Holtkamp K, Burger R, Reichert S, Taurines R, Romanos M, Gerlach M, Egberts K (2017):
Therapeutic Drug Monitoring in Children and Adolescents Under Pharmacotherapy With Olanzapine in Daily Clinical Practice.
Ther Drug Monit. 2017 Jun;39(3):273-281

TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. Schoretsanitis G, Paulzen M, Unterecker S, Schwarz M, Conca A, Zernig G, Gründer G, Haen E, Baumann P, Bergemann N, Clement HW, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud-Sirot E, Laux G, Messer T, Mössner R, Müller MJ, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Silva Gracia M, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Waschgler R, Zurek G, Hiemke C (2018):
TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians.
World J Biol Psychiatry. 2018 Apr;19(3):162-174

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P (2018):
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.
Pharmacopsychiatry. 2018 Jan;51(1-02):e1